Uncategorized
Avedro resubmits NDA for KXL system for corneal cross-linking
Avedro has resubmitted a new drug application for riboflavin ophthalmic solution/KXL system for corneal cross-linking to the FDA, according to a press release. In March, the FDA issued a second complete response letter asking questions about the design of the KXL system and its equivalence to the clinical study device.